| Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations |
166 |
| Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi |
103 |
| Targeting Macrophages in Cancer: From Bench to Bedside |
85 |
| Immuno-Oncology: Emerging Targets and Combination Therapies |
69 |
| The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity |
59 |
| Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication |
51 |
| Recent Advances in the Treatment of Breast Cancer |
50 |
| Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell invasion and Metastasis |
49 |
| Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches |
44 |
| Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway |
43 |
| Role of Matrix Metalloproteinases in Angiogenesis and Cancer |
43 |
| The Origin and Functions of Exosomes in Cancer |
42 |
| Updates in the Clinical Development of Epacadostat and Other Indoleamine 3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers |
42 |
| YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma |
41 |
| The Influence of Metabolism on Drug Response in Cancer |
40 |
| Osteosarcoma: Accelerating Progress Makes for a Hopeful Future |
40 |
| CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors |
39 |
| Defining the Role of Solid Stress and Matrix Stiffness in Cancer Cell Proliferation and Metastasis |
39 |
| Unraveling the Role of Angiogenesis in Cancer Ecosystems |
38 |
| Transforming Growth Factor-beta-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis |
37 |
| Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer |
36 |
| DNA Damage, Repair, and Cancer Metabolism |
36 |
| Cancer Stem Cell Metabolism and Potential Therapeutic Targets |
36 |
| Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance |
35 |
| Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis |
35 |
| Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics |
35 |
| Gene Therapy Leaves a Vicious Cycle |
34 |
| Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma |
34 |
| Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies |
34 |
| Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications |
34 |
| Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis |
33 |
| Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
33 |
| Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation |
33 |
| Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases |
31 |
| Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy |
31 |
| EMT and Stemness in Tumor Dormancy and Outgrowth: Are They Intertwined Processes? |
31 |
| Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology |
30 |
| Inflammation and Metabolism in Cancer Cell-Mitochondria Key Player |
30 |
| Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities |
29 |
| Targeting the Bcl-2 Family in B Cell Lymphoma |
28 |
| Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance |
28 |
| Periostin: A Matricellular Protein with Multiple Functions in Cancer Development and Progression |
28 |
| NAD Metabolism in Cancer Therapeutics |
28 |
| Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors |
28 |
| SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer |
27 |
| Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy |
27 |
| DNA-PK as an Emerging Therapeutic Target in Cancer |
27 |
| Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices |
27 |
| Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells |
27 |
| PVT1 Promotes Cancer Progression via MicroRNAs |
27 |
